210832-85-2

Basic information

• Product Name: 2-Bromo-1-(4-morpholinophenyl)-1-ethanone
• Synonyms: 2-BROMO-1-(4-MORPHOLINOPHENYL)-1-ETHANONE;BUTTPARK 146\50-45;2-Bromo-1-(4-morpholin-4-ylphenyl)ethanone;4-(Morpholin-4-yl)phenacyl bromide;4-(Morpholin-4-yl)phenacyl bromide 97%;2-Bromo-1-(4-morpholinophenyl)ethanone;2-Bromo-4'-morpholinoacetophenone;2-Bromo-4'-(morpholin-4-yl)acetophenone, 2-Bromo-1-[(4-morpholin-4-yl)phenyl]ethan-1-one
• CAS NO: 210832-85-2
• Molecular Formula: C₁₂H₁₄BrNO₂
• Molecular Weight: 284.15
• Product Categories: blocks;Bromides;pharmacetical;Acetyl Halides;Phenyls & Phenyl-Het;Acetyl Halides;Phenyls & Phenyl-Het
• Mol File: 210832-85-2.mol

Chemical Properties

• Melting Point: 112 °C
• Boiling Point: 418.845 °C at 760 mmHg
• Flash Point: 207.111 °C
• Appearance: /
• Density: 1.439 g/cm³
• Vapor Pressure: 3.18E-07mmHg at 25°C
• Refractive Index: 1.581
• Storage Temp.: Keep Cold
• Sensitive: Lachrymatory
• CAS DataBase Reference: 2-Bromo-1-(4-morpholinophenyl)-1-ethanone(CAS DataBase Reference)
• NIST Chemistry Reference: 2-Bromo-1-(4-morpholinophenyl)-1-ethanone(210832-85-2)
• EPA Substance Registry System: 2-Bromo-1-(4-morpholinophenyl)-1-ethanone(210832-85-2)

Safety Data

• Hazard Codes: C
• Statements: 36/37/38-34
• Safety Statements: 26-36/37/39-45
• Hazardous Substances Data: 210832-85-2(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
2-Bromo-1-(4-morpholinophenyl)-1-ethanone is used as a reagent or intermediate for the synthesis of various pharmaceuticals. Its unique structure allows for the development of new drugs with potential therapeutic applications.
Used in Agrochemical Industry:
In the agrochemical sector, 2-Bromo-1-(4-morpholinophenyl)-1-ethanone serves as a key intermediate in the production of agrochemicals, contributing to the development of effective pest control agents and other agricultural products.
Used in Organic Synthesis:
2-Bromo-1-(4-morpholinophenyl)-1-ethanone is utilized as a building block in organic synthesis, enabling the creation of a wide range of organic compounds for various applications across different industries. Its presence of bromine and morpholine groups enhances its reactivity and compatibility in synthetic processes.

InChI:InChI=1/C12H14BrNO2/c13-9-12(15)10-1-3-11(4-2-10)14-5-7-16-8-6-14/h1-4H,5-9H2

Upstream product

• 210832-82-9 2,2-Dibromo-1-(4-morpholin-4-yl-phenyl)-ethanone 
• 39910-98-0 4-morpholinoacetophenone 

Downstream Products

• 924899-53-6 2-(4-morpholinophenyl)-2-oxoethyl acetate 
• 1037828-58-2 4-[4-(1H-imidazol-4-yl)phenyl]morpholine 
• 1222343-69-2 C₁₉H₁₉N₃O₂S 
• 1415695-53-2 C₁₉H₁₈FN₃OS 
• 1601469-05-9 2-(2-(4-(4-morpholinophenyl)thiazol-2-yl)hydrazono)-3-(2-nitrophenyl)propanoic acid 
• 1601469-04-8 2-(2-(4-(4-morpholinophenyl)thiazol-2-yl)hydrazono)-3-(2-nitrophenyl)propanoic acid 

Relevant articles and documents

TGF-betaR1 inhibitor and application thereof

The invention belongs to the field of medical chemistry, and particularly relates to a compound serving as a TGF-betaR1 inhibitor and application of the compound. Specifically, the invention providesa compound shown as a formula I or an isomer, a pharmaceutically acceptable salt, a solvate, a crystal or a prodrug thereof, a preparation method of the compounds, a pharmaceutical composition containing the compounds and application of the compounds or the composition to treatment and/or prevention of TGF-betaR1 related diseases, such as cancers, tissue hyperplasia diseases, fibrosis and inflammatory diseases. The compound provided by the invention shows significant inhibitory activity on TGF-betaR1 kinase, and is very expected to become a therapeutic agent for TGF-betaR1 related diseases.

SUBSTITUTED AMINOTHIAZOLES AS INHIBITORS OF NUCLEASES

The invention provides compounds represented by the structural formula (1): wherein R1, R2, R3, R4, R5, R6 are as defined in the claims. The compounds are inhibitors of nucleases, and are useful in particular in a method of treatment and/or prevention of proliferative diseases, neurodegenerative diseases, and other genomic instability associated diseases.

Photo- and PH-switchable fluorescent diarylethenes based on 2,3-diarylcyclopent-2-en-1-ones with dialkylamino groups

New dialkylamino groups-comprising diarylethenes of 2,3-diarylcyclopent-2-en-1-one (DCP) series have been synthesized and its photochromic, fluorescent as well as acidochromic features have been investigated. It was shown that photochromic properties of t

Structural design, synthesis and structure-activity relationships of thiazolidinones with enhanced anti-Trypanosoma cruzi activity

Pharmacological treatment of Chagas disease is based on benznidazole, which displays poor efficacy when administered during the chronic phase of infection. Therefore, the development of new therapeutic options is needed. This study reports on the structural design and synthesis of a new class of anti-Trypanosoma cruzi thiazolidinones (4 a-p). (2-[2-Phenoxy-1-(4-bromophenyl) ethylidene)hydrazono]-5-ethylthiazolidin-4-one (4 h) and (2-[2-phenoxy-1-(4- phenylphenyl)ethylidene)hydrazono]-5-ethylthiazolidin-4-one (4 l) were the most potent compounds, resulting in reduced epimastigote proliferation and were toxic for trypomastigotes at concentrations below 10 μM, while they did not display host cell toxicity up to 200 μM. Thiazolidinone 4 h was able to reduce the in vitro parasite burden and the blood parasitemia in mice with similar potency to benznidazole. More importantly, T. cruzi infection reduction was achieved without exhibiting mouse toxicity. Regarding the molecular mechanism of action, these thiazolidinones did not inhibit cruzain activity, which is the major trypanosomal protease. However, investigating the cellular mechanism of action, thiazolidinones altered Golgi complex and endoplasmic reticulum (ER) morphology, produced atypical cytosolic vacuoles, as well as induced necrotic parasite death. This structural design employed for the new anti-T. cruzi thiazolidinones (4 a-p) led to the identification of compounds with enhanced potency and selectivity compared to first-generation thiazolidinones. These compounds did not inhibit cruzain activity, but exhibited strong antiparasitic activity by acting as parasiticidal agents and inducing a necrotic parasite cell death. Stop the cycle! The attachment of an aryl ring to the iminic carbon produced thiazolidinones that are conformationally more restricted than first-generation thiazolidinones. This enhanced the potency of antiparasitic thiazolidinones, as observed under treatment with compound 4 h where parasite development and invasion in host cells were substantially reduced. Copyright

Switching reversibility to irreversibility in glycogen synthase kinase 3 inhibitors: Clues for specific design of new compounds

Development of kinase-targeted therapies for central nervous system (CNS) diseases is a great challenge. Glycogen synthase kinase 3 (GSK-3) offers a great potential for severe CNS unmet diseases, being one of the inhibitors on clinical trials for different tauopathies. Following our hypothesis based on the enhanced reactivity of residue Cys199 in the binding site of GSK-3, we examine here the suitability of phenylhalomethylketones as irreversible inhibitors. Our data confirm that the halomethylketone unit is essential for the inhibitory activity. Moreover, addition of the halomethylketone moiety to reversible inhibitors turned them into irreversible inhibitors with IC50 values in the nanomolar range. Overall, the results point out that these compounds might be useful pharmacological tools to explore physiological and pathological processes related to signaling pathways regulated by GSK-3 opening new avenues for the discovery of novel GSK-3 inhibitors.

Synthesis and biological evaluation of quinoline salicylic acids as P-selectin antagonists

Leukocyte recruitment of sites of inflammation and tissue injury involves leukocyte rolling along the endothelial wall, followed by firm adherence of the leukocyte, and finally transmigration of the leukocyte across cell junctions into the underlying tissue. The initial rolling step is mediated by the interaction of leukocyte glycoproteins containing active moieties such as sialyl Lewisx (sLex) with P-selectin expressed on endothelial cells. Consequently, inhibition of this interaction by means of a small molecule P-selectin antagonist is an attractive strategy for the treatment of inflammatory diseases such as arthritis. High-throughput screening of the Wyeth chemical library identified the quinoline salicylic acid class of compounds (1) as antagonists of P-selectin, with potency in in vitro and cell-based assays far superior to that of sLex. Through iterative medicinal chemistry, we identified analogues with improved P-selectin activity, decreased inhibition of dihydrooratate dehydrogenase, and acceptable CYP profiles. Lead compound 36 was efficacious in the rat AIA model of rheumatoid arthritis.

A facile protocol for the convenient preparation of amino-substituted α-bromo- and α,α-dibromo arylmethylketones

Amino-substituted arylmethylketones are selectively brominated in sulfuric acid to afford the corresponding dibromomethylarylketones that are then debrominated with diethylphosphite to give the desired bromomethylarylketones in excellent yield.